Thus, it is possible that the mitogenic function of FGF1 can be reduced by a natural product, combination therapy including a natural product with FGF1 might be able to facilitate the clinical application of FGF1 while minimizing the risk of cancer. The gene discussed is FGF1; the disease is cancer.